Imatinib
- PDF / 141,328 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 48 Downloads / 190 Views
1
S
Acute myeloid leukaemia?: case report A man [age stated to be 61 years-old; age at onset not clearly stated] developed acute myeloid leukaemia (AML) during treatment with imatinib for chronic myeloid leukaemia (CML). The man was diagnosed with Philadelphia chromosomepositive (Ph+) chronic-phase CML in November 2004. He began treatment with the tyrosine kinase inhibitor (TKI), imatinib 400mg daily [route not stated]. He achieved a complete molecular response in November 2005. In July 2009, he presented with mild thrombocytopenia and anaemia. Bone marrow aspiration and PCR was carried out and he was diagnosed with Ph- AML. Following discontinuation of imatinib in August 2009, he received induction chemotherapy and achieved complete remission. His AML relapsed in August 2010 and he received salvage chemotherapy. He achieved complete remission but relapsed again in February 2011. At last follow-up, he was receiving supportive care. Author comment: "The development of Ph- AML could be the result of inherent genomic instability or a direct effect of TKI therapy, whereas the possibility that AML occurred by chance cannot be excluded." Georgiou G, et al. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib. Leukemia 26: 824-826, No. 4, Apr 2012. Available from: URL: http://dx.doi.org/10.1038/ 803073382 leu.2011.280 - Greece
0114-9954/10/1410-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 14 Jul 2012 No. 1410
